Engstrom P F, Ryan L M, Falkson G, Haller D G
Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Am J Clin Oncol. 1991 Feb;14(1):33-5. doi: 10.1097/00000421-199102000-00007.
Twenty-three patients with advanced inoperable squamous cell carcinoma of the esophagus were treated with aminothiadiazole (A-TD) 125 mg/m2 weekly plus allopurinol daily in a phase II cooperative group trial. No patients responded to treatment; 17 patients progressed, three showed stable disease, and three were unevaluable. There were no life-threatening hematologic or metabolic toxicities. The median survival from study entry was 5 months. A-TD is not active in advanced squamous cell carcinoma of the esophagus.
在一项II期合作组试验中，23例晚期无法手术切除的食管鳞状细胞癌患者接受了每周125 mg/m²的氨噻二唑（A-TD）治疗，同时每日服用别嘌醇。没有患者对治疗有反应；17例患者病情进展，3例病情稳定，3例无法评估。没有危及生命的血液学或代谢毒性。从进入研究开始计算的中位生存期为5个月。A-TD对晚期食管鳞状细胞癌无活性。
